Exploring the challenges and innovations in CGT product commercialization

“We need to...make sure that more high-value CGTs continue to move forward towards launch and serving patient communities...”

Jokūbas Leikauskas, Editor, Cell & Gene Therapy Insights, speaks to Ted Slocomb, Global Commercial Biopharma Executive, about the challenges and strategies in cell and gene therapy (CGT) product commercialization, focusing on market access, pricing, and health system readiness. They also discuss practices, such as early value demonstration and outcomes-based agreements (OBAs), while exploring future innovations to expand CGT adoption.

Please enter your email to access content Read now